Effect of granulocyte colony-stimulating factor on IL-12 p40 production during chemotherapy for B-cell lineage Non-Hodgkin’s lymphoma patients

Tomomi Toubai¹, Junji Tanaka¹, Shuichi Ota², Takashi Fukuhara³, Satoshi Hashino², Takeshi Kondo², Yusuke Shono³, Masanobu Morioka⁴, Tsugumichi Kawamura⁵, Nobuo Masauzi⁶, Yasutaka Kakinoki⁷, Hajime Kobayashi⁸, Yasuyuki Kunieda⁹, Masaharu Kasai¹⁰, Mitsutoshi Kurosawa¹¹, Masahiro Imamura¹

¹) Department of Hematology and Oncology, Hokkaido University Graduate School of Medicine.
²) Department of Gastroenterology and Hematology, Hokkaido University Graduate School of Medicine.
³) Department of Internal Medicine, Asahikawa City Hospital.
⁴) Department of Internal Medicine, Aiiku hospital.
⁵) Department of Internal Medicine, Hakodate Central Hospital.
⁶) Department of Hematology, Hakodate City Hospital.
⁷) Department of Internal Medicine, Asahikawa Kosei Hospital.
⁸) The fourth department of Internal Medicine, Obihiro Kosei Hospital.
⁹) Department of Internal Medicine, Wakkanai City Hospital.
¹⁰) Department of Hematology, Sapporo Hokuyu Hospital.
¹¹) Department of Internal Medicine, Sapporo Kosei Hospital.

Running title: IL-12 p40 in NHL patients decrease by G-CSF.

Address correspondence to Dr. Tomomi Toubai, Hematology and Oncology, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo, 060-8638, Japan.
Tel: +81-11-706-7214, Fax:+81-11-706-7823
E-mail: ttoubai@hkg.odn.ne.jp.
Abstract

IL-12 is a 70-kDa cytokine comprised of two disulfide-linked proteins (p35 and p40) and is essential for the initiation of effective immune response. Granulocyte-colony stimulating factor (G-CSF) affects the balance in the production of anti-inflammatory cytokines. We investigated the serum IL-12 p40 and IL-12 Mix (p40 and p70) production in 28 patients with B-cell lineage non-Hodgkin’s lymphoma (NHL) treated with chemotherapy (e.g., CHOP regimen) with or without G-CSF administration and 8 healthy volunteers. We found that serum levels of IL-12 p40 (191.2±150.0 pg/ml) and IL-12 Mix (277.4 ±274.5 pg/ml) in the patients before chemotherapy were higher than those in the healthy volunteers (IL-12 p40: 76.4±25.3 pg/ml, IL-12 Mix: 48.5±33.4 pg/ml) (p=0.04 and 0.02, respectively). Next, we examined the serum IL-12 p40 and IL-12 Mix levels in 9 patients receiving chemotherapy with administration of G-CSF (CG group, n=9) and without G-CSF (C group, n=9). Serum IL-12 p40 and IL-12 Mix levels were decreased on 10 days after chemotherapy in both groups, and those in CG groups were significantly lower than those in C group. These results indicated that administration of G-CSF decreased serum IL-12 p40 and IL-12 Mix levels. Overall survival (OS) at 24 months was not significantly different in the two groups (58.3% in group C vs 80.0% in group CG, P=0.67). However, the survival rate of patients at clinical stages III and IV in CG group (n=6, 66.0%) was significantly better than that of patients in C group (n=4, 25.0%) (p=0.02). Long-term administration of G-CSF appears to influence the survival rate by reducing immunosuppressive IL-12 p40 production.

Key words: IL-12, IL-12 p40, IL-12 p35, non-Hodgkin’s lymphoma, G-CSF
Introduction

Interleukin (IL)-12 is a heterodimeric cytokine produced by dendritic cells (DCs), macrophages, polymorphonuclear leukocytes, and keratinocytes (1). IL-12 exerts multiple biologic activities that, besides NK cell activation, also include activation of CD8$^+$ cytotoxic T lymphocytes (CTLs), differentiation of CD4$^+$ T lymphocytes, induction of nitric oxide (NO) production by macrophages, and induction of type 1 responses by Th lymphocyte (2, 3). IL-12 has been shown to possess potent anti-tumor activity in a wide variety of murine tumor models (4-8). IL-12 is a 70-kDa cytokine comprised of two disulfide-linked proteins (p35, which is constitutively expressed, and p40, which is inducible)(9). The genes encoding IL-12 p40 and p35 are located on different human and mouse chromosomes (10). The highly coordinated expression of p40 and p35 genes to form IL-12 (also called p70) in the same cell type at the same time is essential for the initiation of effective immune response. The IL-12 p35 subunit is expressed ubiquitously, whereas expression of the p40 subunit is restricted to IL-12-producing cells (11). The homodimer IL-12 p40 has been found in several studies to be a strong antagonist of IL-12-mediated effects, such as NK cell activity and IFN-γ production (12, 13).

Granulocyte-colony stimulating factor (G-CSF) is a hematopoietic growth factor that stimulates neutrophil proliferation and function (14). In animal models of infections, the administration of G-CSF increased neutrophil count, decreased bacterial load, and improved organ function and survival, as long as G-CSF was given before or, at the latest, immediately after the initiation of infection (15). Therefore, the possibility that G-CSF affects the balance in the production of anti-inflammatory cytokines has been suggested (16-20).

In the present study, we investigated the production of IL-12 p40, IL-12 Mix and other cytokines in patients with B-cell lineage non-Hodgkin’s lymphoma (NHL) treated with CHOP (cyclophosphamide, adriamycin, vincristine, prednisolone) regimen with or without G-CSF.
administration.
Patients and methods

Preclinical study

Serum levels of IL-12 p40 and IL-12 Mix were examined in 8 healthy volunteer and 28 patients with malignant lymphoma. Eleven of the 28 patients were clinical stage I – II, and the other patients were clinical stage III – IV.

Patients’ characteristics

Eighteen adult patients with B-cell lineage NHL were registered in the study between January 1999 to June 2003 at Hokkaido University Hospital and 10 other hospitals. All of the patients were informed of the purpose of the study, which was approved by the institutional review board. The characteristics of the 18 patients are summarized in Table 1. The 18 patients included 10 males and 8 females with a median age of 54 (range, 31-81) years. Patient’s performance status (PS) and clinical stage at diagnosis were 0 (n=10), 1 (n=5), 2 (n=0) 3 (n=2), 4 (n=1) and I (n=3), II ( n=5), III (n=4), IV(N=6), respectively. Three patients showed B-symptoms. Malignancy grading according to the working formulation classification was low grade in 6 patients and intermediate grade in 12 patients. All of the patients received CHOP regimen (cyclophosphamide 750mg/m² on day1, doxorubicin hydrochloride 50mg/m² on day1, vincristine sulfate 1.4mg/m² day1, prednisolone 40mg/m² on day1-5).

Measurement of serum cytokines

IL-12 p40 and IL-12 Mix (p40 and p70) were measured in sera collected before chemotherapy and at 10 days and 17 days after chemotherapy. IL-12 p40 and IL-12 Mix were measured in serum by an enzyme-linked immunosorbent assay (ELISA) using commercially available kits (IL-12 p40: R&D, IL-12 Mix: Endogen). Optical densities were quantified in an ELISA reader and results
expressed in pg/ml.

**Statistical analysis**

Differences between groups were analyzed by Student’s *t* test. Survival curves were plotted according to the method of Kaplan and Meier, and comparison of the curves was performed using the log-rank test. Overall survival (OS) was measured from the date of registration until death or last contact. Event-free survival (EFS) was measured from the date of registration until relapse after CR, death CR, or last contact, whichever occurred first. If a patient did not reach CR by induction chemotherapy, EFS was set at 0. Disease-free survival (DFS) was restricted to patients who achieved CR and was measured from attainment of CR until the date of relapse, death, or last contact, whichever occurred first.
Results

Serum IL-12 p40 and IL-12 Mix levels were increased in patients with non-Hodgkin's lymphoma.

We found that serum IL-12 p40 and IL-12 Mix levels in NHL patients before chemotherapy were higher than those in healthy volunteers (Table 2). Serum IL-12 p40 and IL-12 Mix levels in healthy volunteers (n=8) were 76.4±25.3 pg/ml and 48.5±33.4 pg/ml, respectively, and those in NHL patients before chemotherapy (n=28) were 191.2±150.0 pg/ml and 277.4±274.4 pg/ml, p=0.04 and p=0.02, respectively. The levels in the 17 clinical stage III-IV patients (IL-12 p40: 229.6±163.7 pg/ml, IL-12 Mix: 380.2±304.6 pg/ml) were significantly higher than those in healthy volunteers (P=0.01 and 0.0059, respectively).

Administration of G-CSF decreased serum IL-12 p40 and IL-12 Mix levels after chemotherapy.

To determine the effect of G-CSF on serum IL-12 p40 and IL-12 Mix levels, the patients were divided into a group administered G-CSF (CG group) and a group not administered G-CSF (C group). As shown in Fig.1, serum IL-12 p40 and IL-12 Mix levels decreased at 10 days after chemotherapy in both groups. However, serum IL-12 p40 and IL-12 Mix levels in CG group (IL-12 p40: from 142.0 ± 121.8 pg/ml (34 courses) to 24.6 ± 27.3 pg/ml (10 days, 32 courses) and to 103.3± 59.0 pg/ml (17 days, 22 courses), IL-12 Mix: from 154.2 ± 156.4 pg/ml (34 courses) to 13.3 ± 17.8 pg/ml (10 days, 32 courses) and to 97.5± 75.7 pg/ml (17 days, 22 courses) were significantly lower than those in C group (IL-12 p40: from 168.8 ± 77.4 pg/ml (29 courses) to 49.1 ± 43.2 pg/ml (10 days, 26 courses) and to 167.8± 67.2 pg/ml (17 days, 13 courses), IL-12 Mix: from 222.6 ± 93.3 pg/ml (29 courses) to 48.6 ± 44.1 pg/ml (10 days, 26 courses) and to 226.6± 98.2 pg/ml (17 days, 26 courses) at 10 days and 17 days after chemotherapy (IL-12 p40: p=0.011 (10 days) and p=0.006 (17 days), IL-12 Mix: p=0.0001 (10 days) and p=0.0001 (17 days)). These results showed that administration of G-CSF decreased serum IL-12 p40 and IL-12 Mix levels.
Administration of G-CSF improved the survival of patients with advanced-stage non-Hodgkin’s lymphoma who had decreased IL-12 p40 and IL-12 Mix levels.

We analyzed the association of clinical characteristics with IL-12 p40 and IL-12Mix levels. Interestingly, serum IL-12 p40 level in CG group patients with clinical stages III and IV was significantly decreased after chemotherapy (-95.6±131.1 pg/ml) (16 courses) compared with that in C group patients with clinical stages III and IV (-0.1±35.2 pg/ml) (10 courses) (P=0.035) (Fig.2a). However, serum IL-12 Mix level in CG group patients with clinical stages III and IV was not significantly decreased after chemotherapy (-132.6±160.1 pg/ml) (16 courses) compared with that in C group patients with clinical stages III and IV (-37.0±75.2 pg/ml) (10 courses) (P=0.091) (Fig.2b).

Serum IL-12 p70 levels could not be detected in almost all patients.

We analyzed the association of survival rate with administration of G-CSF. The overall survival (OS) at 24 months was not significantly different in the two groups (58.3% in C group vs 80.0% in CG group, P=0.67) (Figure 3-a). However, the survival rates of G-CSF-treated patients at clinical stages III and IV and of G-CSF-treated patients with intermediate grade were significantly better than those in patients not treated with G-CSF (stages III and IV survival rate: 66.6% vs 25.0%, p=0.02; intermediate grade survival rate: 75.0% vs 37.5%, p=0.04) (Figure 3-b, c).
Discussion

According to the Revised European American Lymphoma (R.E.A.L) classification (21), three types of human B-cell lymphoma originating from naïve, germinal center (CG) and memory B-cells have been identified and designated as mantle cell (MCL), follicular (FL) and marginal zone (MZL) lymphomas, respectively. Airoldi et al. purified malignant B-cells from lymph nodes of MCL, FL and MZL patients and tested then by reverse transcription polymerase chain reaction (RT-PCR) for constitutive expression of IL-12 p35 and p40. All tumors expressed IL-12 p35, whereas IL-12 p40 mRNA was consistently detected in FL and MZL cells but not in MCL cells (22, 23). Schwaller et al. studied IL-12 expression in human lymphomas using predominantly immunohistochemical techniques with mAbs to IL-12 p35, IL-12 p40 and IL-12 p70 and no expression of the IL-12 heterodimer or of its components was detected in the neoplastic cells (24). Studies on IL-12 production by malignant B-cells suggest that the IL-12 p40 gene is constitutively transcribed in some lymphoma entities (FL, MZL), whereas p35 mRNA is always expressed.

In contrast to an early report that few cytokines are expressed in NHL (25), several groups have shown that a wide range of cytokines, at least at a transcriptional level, are expressed in NHL tissue (22, 26-28). The present study highlights the potential significance of the administration of G-CSF affecting IL-12 p40 and IL-12 Mix levels in terms of tumor growth and patient survival. Previous studies reports suggested that IL-12 is only expressed in EBV-associated lymphomas (24,29). However, Jones et al. detected transcripts in 60% of NHL cases and high levels of p40 were associated with a good prognosis, in those cases, although only a small group was analyzed (30). Although we did not examine cytokine gene expression in the lymphoma cells, serum IL-12 p40 level was reduced in the group administered G-CSF and survival rates of G-CSF-treated patients at clinical stages III and IV were superior to those of patients not treated with G-CSF.

Recombinant human granulocyte colony-stimulating factor (rhG-CSF) plays an important role in
changing the mode of in vivo immune responses from type 1 to type 2. In vivo pretreatment with rhG-CSF induces type-2 dendritic cells (DC2) (31) and type-2 T helper cells (Th2) (32). Monocytes also increase in rhG-CSF-mobilized blood and suppress T cell responsiveness in vitro by secreting a potent immunosuppressive cytokine, IL-10 (33, 34). The rhG-CSF has an influence at least indirectly through inducing type-2 immune cells (DC2, Th2), which downregulate production by type-1 cells of rejection-associated cytokines such as IFN-\(\gamma\), IL-2, TNF-\(\alpha\) and IL-12. Egi et al. reported that IL-12p35 expression was greatly inhibited by rhG-CSF treatment in heart allografts by pretransplant host treatment (35). On the other hand, in the same rat heart allograft model, IL-12 p40 was upregulated by rhG-CSF-treated allogeneic blood transfusion but downregulated by transfusion of rhG-CSF-treated isogeneic blood (36). Moreover, Kitayama et al. reported that rhG-CSF pretreatment of rats undergoing heart transplantation was effective in prolonging allograft survival only in tacrolimus treated hosts. Intragraft mRNA expression of interleukin (IL)-12 subunits (p35, p40) at 24 hours after transplantation was significantly downregulated by the addition of rhG-CSF and was associated with suppression of interferon-\(\gamma\) levels on day 6, although other proinflammatory cytokines (TNF-\(\alpha\), IL-1\(\beta\), IL-6, IL-18) and anti-inflammatory cytokines (IL-10, TGF-\(\beta\)) were not (37). Under these circumstances, IL-12 p40 homodimers instead of bioactive IL-12 p70 are secreted more by antigen-presenting cells, which have been shown to act as antagonists of IL-12 receptors (38) and to inhibit IL-12-dependent immune functions in vivo (39, 40). Although our results showed a decrease in IL-12 p40 level after G-CSF administration, these results might indicate a multiplier effect between G-CSF and chemotherapy. Moreover, Hartung et al. reported that TNF-\(\alpha\), IL-12, and IFN-\(\gamma\) release by whole blood in response to endotoxin (lipopolysaccharide) was reduced in all filgrastim-treated donors (41). IL-12 added in vitro to lipopolysaccharide-stimulated blood of filgrastim-treated donors restored IFN-\(\gamma\) and TNF-\(\alpha\) release, suggesting that the anti-inflammatory effect of G-CSF is exerted through IL-12
Recently, the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVAN) group compared the effect of the cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) regimen given every 3 weeks with the effect of the same regimen plus G-CSF in elderly patients with aggressive non-Hodgkin’s lymphoma in a randomized study (42). They found that the survival rate of patients who received the CHOP plus G-CSF regimen was better than that of patients who received the CHOP regimen. In the present study, the survival rate of patients at clinical stages III and IV who received chemotherapy with G-CSF was better than that of patients who received chemotherapy without G-CSF. Also, IL-12 p40 level was significantly decreased in the chemotherapy with G-CSF group. We cannot explain the association between good survival rate and decrease in IL-12 p40 level. However, administration of G-CSF appears to influence survival rate by reducing immunosuppressive IL-12 p40 production in advanced-stage NHL patients.
References


42. Doorduijn JK, van der Holt B, van Imhoff GW, van der Hem KG, Kramer MH, van Oers MH,
Figure legends

Figure 1. Time course of IL-12 p40 and IL-12 Mix levels.
IL-12 p40 (Figure 1-a) and IL-12 Mix (Figure 1-b) levels were decreased after chemotherapy.
IL-12 p40 and IL-12 Mix levels in the G-CSF administration group were significantly decreased compared with the levels in the chemotherapy alone group at 10 days and 17 days after chemotherapy. ( ■: Chemotherapy without G-CSF, ●: Chemotherapy with G-CSF)

Figure 2. Changes in IL-12 p40 and IL-12 Mix levels with G-CSF or without G-CSF after chemotherapy in patients at clinical stages and .
IL-12 p40 level in the G-CSF administration group was significantly decreased on day 17 after chemotherapy (Figure 4-a) but IL-12 Mix level was not significantly different (Figure 4-b). ( ■: Chemotherapy without G-CSF, ●: Chemotherapy with G-CSF)

Figure 3. Event- free survival.
a: Event- free survival (EFS) rates in the chemotherapy with G-CSF group (n=9) and chemotherapy without G-CSF group (n=9). EFS rates in the two groups were not significantly different.
b: Clinical stage and pathology.
Table 1. Patients characteristics.

<table>
<thead>
<tr>
<th></th>
<th>Chemotherapy only group</th>
<th>Chemotherapy+G-CSF group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total evaluable patients</td>
<td>9</td>
<td>9</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>6</td>
<td>4</td>
</tr>
<tr>
<td>Female</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>Median age (range)</td>
<td>52 (31-81)</td>
<td>57 (43-72)</td>
</tr>
<tr>
<td>PS before treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>4</td>
<td>6</td>
</tr>
<tr>
<td>1</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>3</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>4</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Clinical stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>II</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>III</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>IV</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>B symptom</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(+)</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>(-)</td>
<td>9</td>
<td>5</td>
</tr>
<tr>
<td>Unknown</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Working Formulation grading</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>Intermediate</td>
<td>4</td>
<td>8</td>
</tr>
<tr>
<td>IPI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Low intermediate</td>
<td>6</td>
<td>5</td>
</tr>
<tr>
<td>High intermediate</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>High</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Prognosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CR</td>
<td>6</td>
<td>7</td>
</tr>
<tr>
<td>PR</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>NC</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>PD</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
Table 2. Serum IL-12 levels in healthy volunteers and NHL patients.

<table>
<thead>
<tr>
<th></th>
<th>IL-12 p40</th>
<th>IL-12 Mix</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy volunteers</td>
<td>76.4±25.3</td>
<td>48.5±33.4</td>
</tr>
<tr>
<td>(n=8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients</td>
<td>191.2±150.0*</td>
<td>277.4±274.5*</td>
</tr>
<tr>
<td>(n=28)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I – II (n=11)</td>
<td>131.7±107.3</td>
<td>118.6±96.1</td>
</tr>
<tr>
<td>III – IV (n=17)</td>
<td>229.6±163.7*</td>
<td>380.2±304.6*</td>
</tr>
</tbody>
</table>

* p<0.05
Figure 1-a

Chemotherapy with G-CSF

Chemotherapy without G-CSF

p=0.011

p=0.006
Figure 1-b

Chemotherapy with G-CSF

Chemotherapy without G-CSF

p=0.0001

p=0.0001
Clinical stage (I + II)

Chemotherapy with G-CSF (n=3)

Chemotherapy without G-CSF (n=3)

p=0.165

Clinical stage (III + IV)

Chemotherapy with G-CSF (n=16)

Chemotherapy without G-CSF (n=10)

p=0.035
Clinical stage (I + II)

Chemotherapy with G-CSF (n=3)

Chemotherapy without G-CSF (n=3)

p=0.257

Clinical stage (III + IV)

Chemotherapy with G-CSF (n=16)

Chemotherapy without G-CSF (n=10)

p=0.091
Figure 3-a

Chemotherapy with G-CSF (n=9)

Chemotherapy without G-CSF (n=9)

58.3%
Figure 3-b.1: Clinical stage I and II.

Chemotherapy with G-CSF (n=3)

Chemotherapy without G-CSF (n=5)
Figure 3-b.2: Clinical stage III and IV.
Figure 3-b.3: Low grade lymphoma.
Figure 3-b.4: Intermediate grade lymphoma.

Chemotherapy with G-CSF (n=8)

75.0%

Chemotherapy without G-CSF (n=4)

37.5%

P=0.045

(WEEKS)